{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Grade 4 toxicity hypomagnesium experienced by participants related to Cabozantinib. Grade 4 toxicity is life-threatening consequences; urgent intervention indicated.","groups":[{"description":"Cohort 1 - (urothelial progressive disease) Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.\n\nCohort 2 (Bone-only) Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.\n\nCohort 3 (Rare histologies) Patients with non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG000","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"We did not group the adverse events by cohort because we did not expect the cohorts to experience different adverse events as they were all getting the same medication at the same dose. And 68/69 participants were analyzed because one participant was enrolled and deemed ineligible prior to treatment.","reportingStatus":"POSTED","timeFrame":"Median follow-up was 61.2 months","title":"Number of Participants With Grade 4 Toxicity Hypomagnesium Related to Cabozantinib","type":"SECONDARY","unitOfMeasure":"Participants"}